Carlsmed expected to post 40-cent loss per share on 46.5% revenue growth

what happened

Carlsmed, Inc. will publish its results on November 11 for the period ending September 30, 2026. According to a mean estimate from five analysts, compiled by LSEG, the company's revenue is expected to rise 46.5%, to 19.154 million dollars from 13.07 million a year earlier.

The average forecast points to a loss of 40 cents per share, a figure that has been unchanged for the past three months. Analyst ratings on the shares are currently positive: five recommend buy or strong buy, and none recommend hold, sell or strong sell.

The median 12-month price target among analysts is 18.00 dollars, about 24% above the last close of 14.52 dollars. The summary was machine generated on November 9, as reported by Earnings Preview.

why it matters

For investors, the forecast is only part of the picture; the track record matters too. Over the last four quarters the company beat expectations on loss per share each time, so the gap between estimate and actual result is worth watching. A report from a company of this size rarely moves the broader market, but it gives a reference point for the stock.

tags

instruments